In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control

Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0014. Online ahead of print.ABSTRACTJackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271-281. 38071986.PMID:38560905 | DOI:10.7326/J24-0014
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Source Type: research